Andere Sprachen Leap Therapeutics, Inc.

Aktien

A3EMJP

US52187K2006

LPTX

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:45:15 27.06.2024			% 5 Tage	% 1. Jan.
1,77 ^USD	+0,57 %		-9,95 %	-57,42 %

14.05.	LEAP THERAPEUTICS, INC. : HC Wainwright bekräftigt seine Kaufempfehlung	ZM
13.05.	Leap Therapeutics, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Leap Therapeutics, Inc. announced that it has received $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP	15.04.
Leap Therapeutics Announces $40 Million Private Placement	11.04.
Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP	10.04.
Leap Therapeutics Files $200 Million Mixed-Securities Shelf Registration	18.03.
Leap Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	18.03.
Leap Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18.03.
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium	16.01.
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference	03.01.
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients	02.01.
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients	02.01.
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium	12.12.
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference	21.11.
Leap Therapeutics Reports Third Quarter 2023 Financial Results	13.11.
Leap Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
Top Premarket Decliners	16.10.23
Top Premarket Decliners	09.10.23
Leap Therapeutics to Participate at Upcoming Investor Conferences	05.09.23
Leap Therapeutics Reports Second Quarter 2023 Financial Results	15.08.23
Leap Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14.08.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Leap Therapeutics, Inc.

Aktien

A3EMJP

US52187K2006

LPTX

Andere Sprachen

Filter